CAS: 614-96-0; 5-Methylindole

上下游产品

CAS号215589-37-0 2-炔基-4-甲基苯胺 | CAS号52562-50-2 5-甲基吲哚-3-甲醛 | CAS号126759-32-8 5-methyl-2-nitr... | CAS号637-39-8 盐酸三乙醇胺 | CAS号106-49-0 对甲苯胺 | CAS号102-71-6 三乙醇胺 | CAS号107734-14-5 2-ethenyl-4-met... | CAS号65826-95-1 5-甲基二氢吲哚 | CAS号180624-14-0 4-methyl-2-(2-t... | CAS号29289-13-2 2-碘-4-甲基苯胺 | CAS号3484-35-3 5-甲基吲哚啉-2-酮 | CAS号475102-14-8 5-甲基-1H-吲哚-2-硼酸... | CAS号18028-56-3 1,4,6-trimethyl... | CAS号18210-83-8 3-(5-methylindo... | CAS号4692-99-3 6-甲基靛红酸酐 | CAS号1912-47-6 2-(5-甲基-1H-吲哚)-3-乙酸 | CAS号52562-50-2 5-甲基吲哚-3-甲醛 | CAS号65826-95-1 5-甲基二氢吲哚 | CAS号614-96-0 5-甲基吲哚 | CAS号1003708-62-0 3-溴-5-甲基-1H-吲哚

5-Methyl-1-Tosyl-1H-Indole置于甲酸,(4,4'-Di-Tert-Butyl-2,2'-Dipyridyl)-Bis-(2-Phenylpyridine(-1H))-Iridium(Iii) Hexafluorophosphate,N,N-二异丙基乙胺体系中,用 乙腈 作为反应溶剂,化学反应 24.0H,以84%的收率获得产物5-甲基吲哚
参考文献:电子转移光氧化还原催化:氮杂杂芳环光活化还原脱磺酰化的发展.
标题:电子转移光氧化还原催化:氮杂杂芳环光活化还原脱磺酰化的发展.
摘要:在这里,我们报告通过光致电子转移和氢原子转移氮杂杂芳环脱磺酰的协议.该通用方案具有广泛的底物范围,并且具有中等至非常好的产率.该方法的实用性通过同时包含脂族和芳族磺酰胺的分子的化学选择性去磺酰化来证明.
DOI:10.1002/adsc.202000578

专利信息

专利号:US-12024731-B2
优先权日:2017-05-03
标 题 :Methods and enzyme catalysts for the synthesis of non-canonical amino acids
发明人：BOVILLE CHRISTINA E; BRINKMANN-CHEN SABINE; BULLER ANDREW R; ROMNEY DAVID K; PRIER CHRISTOPHER K; KOCH PHILIPP; SCHEELE REMKES A
权利人:CALIFORNIA INST OF TECHN
摘要:The present disclosure provides methods for preparing β-substituted tryptophan compounds. The methods include: combining i) an unsubstituted indole or a substituted indole, ii) a β-substituted serine, and iii) a tryptophan synthase β-subunit (i.e., a TrpB); and maintaining the resulting mixture under conditions sufficient to form the β-substituted tryptophan. The TrpB contains at least one amino acid mutation which promotes formation of an amino-acrylate intermediate. New TrpB variants and new β-substituted tryptophan analogs are also described.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:US-7786156-B2
优先权日:2004-01-28
标 题 :Synthesis methods and intermediates for the manufacture of Rizatriptan
发明人：MARTIN PIERRE; BERENS ULRICH; BOUDIER ANDREAS; DOSENBACH OLIVER
权利人:RATIOPHARM GMBH
摘要:The invention relates to a process for the manufacture of an 1,2,4-triazol-1-yl compound of the formula [A], n nor a salt thereof, wherein each of R3 and R4 is hydrogen or lower alkyl, said process comprising reacting a hydrazine compound of the formula [B]n n nwherein R is hydrogen or acyl, R2 is hydrogen or a protecting group, are hydrogen or lower alkyl, and R6 is hydrogen or COOR7, or a salt thereof, with a 1,2,4-triazolyl forming reagent.n n In addition, novel intermediates for the synthesis of the anti-migraine agent Rizatriptan and methods for their synthesis are presented.

专利号:WO-2024185775-A1
优先权日:2023-03-06
标 题:Long-chain alkenyloxy–substituted benzoyl derivative and oligonucleotide synthesis method using same
发明人：OKADA YOHEI; INANAGA KAZATO; SHOJI Yukiya; MIZUFUNE HIDEYA; SUDO TATSUYA; ADACHI Sota; HOSOI Kazushi
权利人:SPERA PHARMA INC; TOKYO UNIV OF AGRICULTURE AND TECHNOLOGY
摘要:The purpose of the present invention is to provide a novel pseudo–solid phase protecting group that can be used in liquid-phase oligonucleotide synthesis. The purpose of the present invention is also to provide an oligonucleotide synthesis method that uses a novel pseudo–solid phase protecting group.　The present invention provides a compound represented by formula (1) (in which R represents a C14–60 alkenyl group, n represents 2 or 3, m represents 0 or 1, p represents 1 or 2, X represents C, N, O, or S, Y represents a single bond or B(CH 2 ) t * or may form a ring with X, and Z represents a single bond or (CH 2 ) s (s being an integer from 1 to 5)). The present invention also provides an oligonucleotide production method that uses the compound.

专利号:WO-2025082632-A1
优先权日:2023-10-16
标 题:Method and composition for oligonucleotide synthesis
发明人：SAITO MASAHARU
权利人:BACHEM HOLDING AG
摘要:The invention pertains to a method for the synthesis of oligonucleotides using pseudo solid-phase protecting groups, wherein said method comprises a step of subjecting a solution comprising a component (C-0)# to one or more aqueous extractions, wherein the organic phase comprises the component (C-0)#. Said component (C-0)# is a nucleoside or an oligonucleotide, which is covalently bonded to a pseudo solid-phase protecting group and comprises a free backbone hydroxyl group. The aqueous phase of each of said one or more aqueous extractions has a pH-value in the range of 4-7.

专利号:EP-4605403-A1
优先权日:2022-10-17
标 题:Method and composition for oligonucleotide synthesis
发明人：SAITO MASAHARU; TAKEDA KAZUTAKA; OKADA YOHEI; LUTHER ANATOL
权利人:BACHEM HOLDING AG
摘要:The invention pertains to methods for the synthesis of oligonucleotides using pseudo solid-phase protecting groups, wherein said method comprises at least one aqueous extraction carried out in the presence of one or more amide solvents SA, wherein each amide solvent SA is an amide solvent comprising one or more alkyl groups, wherein these one or more alkyl groups together comprise in total 6−24 carbon atoms. The invention further pertains to compositions comprising an oligonucleotide which is covalently bonded to a pseudo solid-phase protecting group and a mixed solvent comprising on or more of the aforementioned amide solvents SA.